文献速递肝病

肝硬化患者非恶性门静脉血栓由内膜纤维化构成,部分伴富纤维蛋白血栓

Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
PubMed 文献 · Hepatology · 2021-12-05

该研究对肝硬化肝移植患者的非恶性门静脉血栓进行组织学、免疫组化和扫描电镜分析,发现所有血栓均表现为增厚纤维化的血管内膜,仅约三分之一病例在纤维化内膜上附加富纤维蛋白血栓。临床特征包括估计血栓年龄和抗凝使用与富纤维蛋白血栓的存在无关。作者推测这一结构差异可能解释为何抗凝治疗并非所有门静脉血栓都能再通。

要点

  • 肝硬化门静脉血栓均存在内膜纤维化,部分病例叠加富纤维蛋白血栓
  • 富纤维蛋白血栓仅见于约三分之一病例,与抗凝使用和血栓年龄无关
  • 血栓结构差异可能解释抗凝治疗后门静脉再通不一致

核心结论

  • 肝硬化患者门静脉血栓由内膜纤维化构成,仅约三分之一病例附加富纤维蛋白血栓。
  • 临床特征包括估计血栓年龄和抗凝使用与富纤维蛋白血栓的存在无关联。

研究设计与样本

  • 纳入16例前瞻性和63例回顾性收集的肝硬化肝移植患者非恶性门静脉血栓样本。
  • 采用组织学、免疫组化和扫描电镜评估血栓结构与成分,并重新分析最近一次CT的血栓特征。

主要发现

  • 所有样本均显示增厚、纤维化的血管内膜。
  • 富纤维蛋白血栓存在于9/16前瞻性病例和21/63回顾性病例的纤维化内膜之上。
  • 少数纤维化区域局灶阳性染色:纤维蛋白/纤维蛋白原16%、血管性血友病因子(VWF)10%、CD61(血小板)21%。
  • 多数富纤维蛋白区域阳性染色:纤维蛋白/纤维蛋白原100%、VWF 77%、CD61 100%。

临床怎么用

  • 认识门静脉血栓以内膜纤维化为基础的结构特征,理解抗凝治疗可能无法使所有血栓再通。

局限性

  • 样本来自肝移植患者,可能存在选择偏倚。
  • 回顾性收集样本占多数,临床资料和血栓年龄估计可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Portal vein thrombosis (PVT) is a common complication of cirrhosis. The exact pathophysiology remains largely unknown, and treatment with anticoagulants does not lead to recanalization of the portal vein in all patients. A better insight into the structure and composition of portal vein thrombi may assist in developing strategies for the prevention and treatment of PVT. APPROACH AND RESULTS: Sixteen prospectively and 63 retrospectively collected nonmalignant portal vein thrombi from patients with cirrhosis who underwent liver transplantation were included. Histology, immunohistochemistry, and scanning electron microscopy were used to assess structure and composition of the thrombi. Most recent CT scans were reanalyzed for thrombus characteristics. Clinical characteristics were related to histological and radiological findings. All samples showed a thickened, fibrotic tunica intima. Fibrin-rich thrombi were present on top of the fibrotic intima in 9/16 prospective cases and in 21/63 retrospective cases. A minority of the fibrotic areas stained focally positive for fibrin/fibrinogen (16% of cases), von Willebrand factor (VWF; 10%), and CD61 (platelets, 21%), while most of the fibrin-rich areas stained positive for those markers (fibrin/fibrinogen, 100%; VWF, 77%; CD61, 100%). No associations were found between clinical characteristics including estimated thrombus age and use of anticoagulants and presence of fibrin-rich thrombi. CONCLUSION: We demonstrate that PVT in patients with cirrhosis consists of intimal fibrosis with an additional fibrin-rich thrombus in only one-third of cases. We hypothesize that our observations may explain why not all portal vein thrombi in patients with cirrhosis recanalize by anticoagulant therapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology. 2021. PMID: 34559897. doi:10.1002/hep.32169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。